Abstract:Background: The London patient (participant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not express CCR5 (CCR5Δ32/Δ32); remission was reported at 18 months after analytical treatment interruption (ATI). Here, we present longer term data for this patient (up to 30 months after ATI), including sampling from diverse HIV-1 reservoir sites. Methods: We used ultrasensitive viral load assays of plasma, semen, and cerebrospinal fluid (CSF) samples to detect HIV-1 RNA. In gut biopsy samples and lymph-node tissue, cell-copy number and total HIV-1 DNA levels were quantified in multiple replicates, using droplet digital PCR (ddPCR) and quantitative real-time PCR. We also analysed the presence of intact proviral DNA using multiplex ddPCR targeting the packaging signal (ψ) and envelope (env). We did intracellular cytokine staining to measure HIV-1-specific T-cell responses. We used low-sensitive and low-avidity antibody assays to measure the humoral response to HIV-1. We predicted the probability of rebound using a mathematical model and inference approach. Findings: HIV-1 viral load in plasma remained undetectable in the London patient up to 30 months (last tested on March 4, 2020), using an assay with a detection limit of 1 copy per mL. The patient's CD4 count was 430 cells per μL (23·5% of total T cells) at 28 months. A very low-level positive signal for HIV-1 DNA was recorded in peripheral CD4 memory cells at 28 months. The viral load in semen was undetectable in both plasma (lower limit of detection [LLD] <12 copies per mL) and cells (LLD 10 copies per 106 cells) at 21 months. CSF was within normal parameters at 25 months, with HIV-1 RNA below the detection limit (LLD 1 copy per mL). HIV-1 DNA by ddPCR was negative in rectum, caecum, and sigmoid colon and terminal ileum tissue samples at 22 months. Lymph-node tissue from axilla was positive for the long-terminal repeat (33 copies per 106 cells) and env (26·1 copies per 106 cells), negative for ψ and integrase, and negative by the intact proviral DNA assay, at 27 months. HIV-1-specific CD4 and CD8 T-cell responses have remained absent at 27 months. Low-avidity Env antibodies have continued to decline. Mathematical modelling suggests that the probability of remission for life (cure) is 98% in the context of 80% donor chimerism in total HIV target cells and greater than 99% probability of remission for life with 90% donor chimerism. Interpretation: The London patient has been in HIV-1 remission for 30 months with no detectable replication-competent virus in blood, CSF, intestinal tissue, or lymphoid tissue. Donor chimerism has been maintained at 99% in peripheral T cells. We propose that these findings represent HIV-1 cure. Funding: Wellcome Trust and amfAR (American Foundation for AIDS Research).

Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States

"This is actually a really unique moment in time": Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions – A Qualitative Interview Study in the United States

Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366

Long-acting HIV Fusion Inhibitor Albuvirtide Combined with Ritonavir-Boosted Lopinavir for HIV-1-infected Patients after Failing the First-Line Antiretroviral Therapy: 48-Week Randomized, Controlled, Phase 3 Non-Inferiority TALENT Study

The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy

Assessing understandings and perceptions of HIV cure among peer navigators and treatment officers in Australia

Project Khanya: a randomized, hybrid effectiveness-implementation trial of a peer-delivered behavioral intervention for ART adherence and substance use in Cape Town, South Africa

'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States

Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United States

People with HIV at the end-of-life and their next-of-kin/loved ones are willing to participate in interventional HIV cure-related research

Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk

Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium

Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

Acceptance and Factors Associated with Participation in Functional Cure–Related Trials among People Living with HIV: A Cross-sectional Study in Southern China

Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States

Acceptance and Factors Associated to Participation in Functional Cure–Related Trials Among People Living With HIV: A Cross-Sectional Study in Southern China

Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV

"They Have to Make an Effort Too": What Decliners Can Teach Us About HIV Cure/Remission-Related Clinical Trials? Results from a French Qualitative Study

A Comprehensive Analysis of HIV Treatment Efficacy in the ACTG 175 Trial Through Multiple-Endpoint Approaches

Informed consent to HIV cure research

The impact of analytical treatment interruptions and trial interventions on time to viral re‐suppression in people living with HIV restarting ART in cure‐related clinical studies: a systematic review and meta‐analysis